CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Amgen's Sjogren's drug cuts disease activity in trial

By Reuters News

Nov 11 (Reuters) - Amgen AMGN.O said on Wednesday a detailed late-stage trial data showed its experimental drug for the Sjogren's disease significantly reduced disease activity in patients.

  • This builds on the initial results reported by the company in September for the drug, dazodalibep

  • The Sjogren's disease is an autoimmune condition that attacks the body's moisture-producing glands, causing dry eyes and mouth, fatigue and pain

  • Patients on 1,500 mg of dazodalibep every four weeks lowered their disease activity score by 5.6 points over 48 weeks, versus 3.8 points for placebo — a gap of 1.8 points

  • Those on 3,000 mg dose every 12 weeks saw a 5.2-point drop, a 1.4-point gap versus placebo

  • Both doses met the trial's main goal, and the effect appeared as early as week four, Amgen said

  • The trial enrolled 648 patients with moderate-to-severe systemic disease activity

  • According to the Sjogren's Foundation, the condition affects up to 4 million Americans and about 90% of diagnosed adults are women

  • Novartis NOVN.S and Johnson & Johnson JNJ.N are also developing drugs to treat the Sjogren's disease, which has no approved treatments in the US

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.